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Long-acting drug nanosuspension formulations are coming to the fore as controlled release strategies for several 
medical conditions and as a preventative measure against HIV infection. However, such delivery systems must, by 
necessity, be given by hypodermic injection, typically into muscle. This poses problems for patients who are needle-
phobic, given that injections have to be administered on a weekly or monthly basis. Needle-stick injuries, inappropriate 
reuse of needles, and poor disposal practices are major challenges in developing countries. Dissolving microneedles 
(MNs) are capable of delivering high drug doses, if suitably designed and formulated, and are also capable of 
delivering nanoparticles (NPs) into viable skin. Given that such microneedles are minimally invasive and self-disabling, 
the potential for major enhancement in patient care and compliance exists. In this review, we explore the key 
considerations in the development of these combination drug delivery systems. 
 
Introduction 
MNs are minimally invasive devices that by-pass the stratum corneum (SC) barrier of the skin, thus granting 
access to the dermal microcirculation and antigen-presenting XXXXX located in the inferior layers of the skin. MNs 
comprise multiple micron-scale projections positioned on a baseplate in various geometries. When applied to the 
skin, they painlessly puncture the SC, creating microscopic aqueous channels through which drugs can diffuse. 
MNs are long enough to penetrate the SC (50–900 Mm in height, up to 2000 MN cm–2), but short enough to avoid 
stimulation of dermal nerves. They are manufactured from various materials (e.g., silicon, metal, or polymer using 
microfabrication techniques [1–3]. Originally described in a 1970s patent and finally realized in practical terms 
during the late 1990s [4], MNs (Figure 1) are currently of great interest because of several advantages that they 
have over traditional methods of drug delivery. Some of these advantages include the ability to painlessly 
administer the active pharmaceutical ingredient (API), bypass the hepatic first-pass metabolism, and the extension 
of the variety of drug types that can be delivered both intra- and transdermally. 
The first substance delivered using MNs was the low-molecular-weight compound, calcein [4]. Multiple 
investigations rapidly followed, leading to the current ever-growing body of evidence for the significant drug 
delivery capabilities of MNs. Although a variety of strategies has been used (Figure 2), MNs fabricated from silicon 
and metal continue to be extensively investigated for drug delivery. Their use typically involves the pretreatment of 
skin, followed by application of a topical solution, gel, or patch containing the drug to be delivered [5–7]. Although 
this conventional ‘poke and patch’ methodology has progressed somewhat from the original studies, it has been 
recognized that such a cumbersome two-step application process is a major drawback [8]. 
To create a one-step application process, solid MNs have been coated with the material to be delivered. Coated 
MNs have been used for the delivery of several different compounds, including fluorescein sodium [9], salmon 
calcitonin [10], desmopressin [11], parathyroid hormone (PTH) [12], and DNA/RNA [13,14], among others. Aside 
from this, because of the limited drug-loading capacity of this method, coated MNs are more frequently used for the 
delivery of highly potent molecules and vaccines. 
Research into hollow MNs has focused mainly on array design and characterization, with several sophisticated 
engineering strategies presented [15–18]. However, a major limitation to their use is the potential blockage of the 
MN bore by compressed dermal tissue upon insertion, reducing drug release [18]. 
Dissolving MNs have been used to deliver several small-molecule drugs, including caffeine, lidocaine, 
theophylline, and metronidazole [19]. Additionally, they have been used to specifically target various clinical needs 
by the delivery of several biopharmaceutical molecules, including low-molecular-weight heparins [20], insulin [21], 
leuprolide acetate [22], erythropoietin [23], and human growth hormone [24]. A central criticism of the dissolving 
platform was the perceived inability to deliver therapeutically relevant doses of low-potency drug substances [25]. 
However, McCrudden et al. have taken steps to address these concerns, having successfully delivered 
therapeutically relevant doses of ibuprofen sodium in a rat model [26]. 
Hydrogel-forming MNs have been demonstrated to proficiently deliver both small molecules, such as 
metronidazole and theophylline, and larger molecules, such as insulin and proteins [8]. The benefit of the hydrogel 
system is that the MN swelling rate can be controlled by altering the polymer cross-linked density, thus conferring 
the ability to govern drug release rate, which can be tailored for specific drugs. The delivered dose is not limited by 
what can be loaded into the needles themselves, given that the drug is contained within an attached solid drug 
reservoir. Accordingly, sustained delivery of high drug doses is readily achievable. 
As can be seen from Table 1, there has been a range of completed and ongoing clinical trials involving the use of 
MNs. Although several investigations involving humans have considered the perception, safety, and practical 
applications of MN technology [27,28] and a few human volunteer trials have studied MN-mediated transdermal 
drug delivery [12,29], the predominant focus in the field to date has been on vaccines [30–33]. This is hardly 
surprising, given the potential for a stable, dry-state formulation, the avoidance of needle-stick injuries common 
with hypodermic syringes, dose-sparing through direct targeting of the abundance of professional antigen-
presenting cells in viable skin, and the self-disabling nature of dissolving MNs. Consequently, several clinical trials 
covering the use of MNs for vaccine delivery are detailed in Table 1. Influenza intradermal vaccination has been 
extensively studied because there is a constant demand for a seasonal vaccine. These trials were conducted around 
the world in thousands of volunteers, including a randomized, open-label Phase 2 clinical trial (978 healthy adults) 
[34], a Phase 3 randomized, double-blind trial (2255 healthy adults) [35], and a Phase 2/3 trial in older individuals 
(aged 60 years and older) [36]. The obtained results suggested that the MN-based vaccine provided an equivalent 
(and, in some cases, superior) immune response compared with the conventional intramuscular vaccine. 
MN vaccines have the potential to revolutionize vaccination, especially in the developing world. However, in 
studies where the delivery of therapeutic drug substances using MNs has been exemplified, the focus has tended to 
be on illustration of the capability of MNs to deliver a substance with particular physicochemical characteristics 
and little mention is typically made of the actual amount delivered or its relevance to therapeutic human doses. 
Vaccines tend to be potent and, thus, delivery of even microgram quantities of antigen, antigen/adjuvant 
combination, virus-like particle, or even DNA is often sufficient to elicit an immune response, especially when 
targeted to the viable epidermis and/or dermis. This means that small, postage stamp-sized MN patches that can 
be inserted into the skin by fairly gentle thumb pressure are sufficient to achieve successful vaccination. 
In addition to MN-mediated vaccination, the delivery of insulin using MNs has been extensively studied in 
clinical trials (Table 1). The use of MNs for this purpose provided better patient compliance compared with 
traditional subcutaneous injections. In addition, clinical trials showed that the MN-mediated administration of 
insulin enabled faster uptake of this molecule and equivalent bioavailability/blood-glucose effects compared with 
subcutaneous administrations [37,38]. 
The use of MN devices for clinically relevant does in human volunteers has not been extensively studied, as 
shown in Table 1. However, recent work in the field has focused strongly on the transdermal delivery of 
therapeutically relevant doses of drugs using MN patches. Plasma levels in animal models have been measured 
and extrapolated to estimate suitable patch sizes for the achievement of therapeutic plasma levels in humans 
[18,20,22]. Given that most commonly used small-molecule drugs tend to require oral doses in the range of tens to 
hundreds of milligrams daily, the patch sizes estimated have ranged from 10 cm2 to 30 cm2. Such patch sizes are 
well within the range of marketed transdermal patches. Indeed, Novartis market Nicotinell® (nicotine) patches of 
30 cm2 (www.nicotinell.co.uk), whereas Janssen market Duragesic® CII (fentanyl) patches of 32 and 42 cm2 
(www.duragesic.com). It was recently shown that human volunteers can insert the MNs of large patches as 
efficiently and reliably as those on smaller patches, thus making such a delivery system viable [39]. 
The ability to deliver high drug doses has raised interest in the possibility of delivering long-acting drug 
nanosuspensions intradermally without the need for a conventional hypodermic needle injection. Nanosuspensions 
are, in simple terms, aqueous suspensions of NPs made from solid-drug crystals stabilized with a coating of 
surfactant and/or polymer. They are typically up to 90% w/w pure drug and can be prepared by ‘top-down’ (e.g., wet 
milling or high-pressure homogenization) or ‘bottom-up’ (solution-based nanoprecipitation) methods [40–42]. 
Preparation of solid-drug NPs can be used to improve aqueous solubility for applications in enhanced oral or 
pulmonary bioavailability. However, if one selects a potent drug with relatively poor aqueous solubility and can 
tailor particle size appropriately, an injectable preparation capable of sustained delivery of clinically relevant drug 
doses for up to 3 months from a single injection can be produced. The particles are deposited as a depot and slowly 
release drug for absorption into the systemic circulation as they dissolve in interstitial fluid. If enough particles can 
be deposited, then therapeutic plasma levels can be maintained for prolonged periods [40–42]. 
Originally used for the hormonal treatment of endometriosis, long-acting drug nanosuspensions then found use 
in the management of schizophrenia. Most interestingly, however, this formulation type is now undergoing clinical 
trials for the prevention and treatment of HIV [42]. It is because of this exciting new indication that the mode of 
nanosuspension delivery has come sharply into focus. Oral administration of nanosuspensions does not allow 
sustained drug absorption over weeks or months and, thus, such products have typically been administered 
subcutaneously or, if higher volumes are required (up to 2.7 ml from a single injection) to deliver therapeutic doses, 
intramuscularly. Hypodermic needle injections cause problems in developing countries, in particular, because of the 
lack of skilled healthcare personnel, frequency of needle-stick injuries, inappropriate reuse of needles, and poor 
disposal practices. An alternative, minimally invasive, self-disabling, delivery system that avoids such problems 
would not only be particularly useful in low-resource settings, but could also improve compliance in developed 
countries. 
Solid MN arrays have been used to enhance the delivery of microparticle and NP suspensions. However, in these 
cases, the application process requires the application of a solid MN array before administration of a formulation 
containing the suspension into the treated area [17,43,44]. A two-step process is not ideal from a patient point of 
view. 
Several examples of hollow MNs for the delivery of nanosuspensions can be found in the literature [45–48]. 
These devices have been extensively studied for the intraocular administration of NPs and microparticles [46–48]. 
However, they require complex pumping systems, which are expensive and difficult to manufacture and could 
present issues for correct use in the absence of skilled healthcare workers in developing countries [2]. The safe and 
hygienic disposal of such systems in low-resource settings might also prove problematic. Coated MNs have limited 
dosing capacity and are also removed from the skin intact, therefore presenting challenges for disposal [2]. 
Diffusion of hydrophobic NPs through swollen hydrogel matrices is likely to be poor, thus ruling that system out 
[8]. However, dissolving MNs have considerable promise in the intradermal delivery of long-acting 
nanosuspensions. 
The literature contains a variety of examples of the use of dissolving MNs for nanosuspension administration 
[49–51]. However, most of these papers focused on the delivery of encapsulated vaccines [49,52,53] or were designed 
as a proof of concept to show the capabilities of MNs to enhance the delivery of particulate formulations through 
the SC [49]. Consequently, basic technical and scientific challenges are being addressed currently, such as: the 
possibility of manufacturing two-layered MN arrays concentrating suspensions in the needle tips or the study 
[54,55] of the fate of NPs administered intradermally [55]. Nevertheless, the delivery of therapeutically relevant 
doses of nanomedicines using dissolving MNs remains relatively unexplored. 
Advantages of a dissolving MN system over conventional needle-and-syringe-based methods for the 
administration of long-acting drug nanosuspensions would include: (i) no requirement for skilled medical personnel 
to administer the dose; (ii) potential for at-home use by patients; (iii) possibility for improved compliance; (iv) 
avoidance of needle-stick injuries; (v) specialized disposal not required; and (vi) possibility for enhanced storage 
stability because of the dried nature of the formulations. 
However, to be a realistic proposition, such a dissolving MN system would need to be able to incorporate a high 
loading of hydrophobic NPs in the needles themselves. Given the viscous nature of the gel formed in skin upon 
needle dissolution, it is unlikely that any NPs in the baseplate upon which the needles were formed would be able 
to diffuse into the viable skin. Doses of several hundred milligrams would, in most cases (apart from hormones), 
have to be delivered into skin upon needle dissolution. If the patch size required to deliver such a dose would, by 
necessity, be greater than that of conventional transdermal patches, then the delivery of a particular drug would 
not be feasible. However, if one considers that the MNs themselves can weigh 10 mg for every cm2 of patch upon 
which they are formed and the drug loading is a minimum of 80% w/w, then 8 mg/cm2 of drug could be delivered 
upon total needle dissolution in skin. If the drug dose for a month of treatment were 300 mg, then the patch size 
would be 37.5 cm2. If the drug dose were 600 mg, then two patches could be applied, one on each arm. This mimics 
the current rilpivirine regimen for HIV prevention, where two injections are given at different sites. Given that 
large MN patches can be reliably applied by human volunteers, the approach appears feasible. However, what 
would be useful would be an indicator confirming when the patch can be removed. A low-cost system would not be 
able to tell when the needles had dissolved, but a moisture sensor or time-dependent color change indicator based 
on average in-skin dissolution time would not add prohibitive expense. 
The needles should dissolve quickly in skin (in <1 h ideally), so as to be convenient for patients. This means that 
the polymer matrix must be carefully chosen so as to provide sufficient mechanical strength to allow ready 
puncture of the SC upon application of relatively gentle pressure, while not being brittle, but must not be slowly 
soluble in the relatively small volume of fluid available in viable skin. Given that possibly >80% by weight of the 
MN might comprise hydrophobic NPs, repulsion of interstitial fluid could be a consideration requiring addition of 
disintegrants to boost MN breakdown. Excipients chosen, including the matrix polymer and water, must not 
significantly alter the characteristics of the particles of the nanosuspension (e.g., size, charge or aggregation status) 
or cause dissolution during manufacture or storage. The excipients should also be biodegradable or of sufficiently 
low molecular weight to allow ready clearance from the body, given that the patch will need to be applied by the 
patient weekly or monthly. Accumulation of excipients in skin or elsewhere in the body would be undesirable and 
would be likely to raise regulatory concerns. Indeed, from a regulatory viewpoint, clinical studies aimed at 
supporting market authorization would need to show that therapeutic blood levels comparative to existing dosage 
forms are achievable, even if the pharmacokinetic patterns differ. Whether regulators would require a sterile or low 
bioburden product, considering that MNs enter viable skin, is not clear as yet. It is likely that a suitable applicator, 
or an in-built method of confirming correct use (MN insertion) would also be required, especially if the product is to 
be used by patients themselves in low-resource settings. In-built feedback mechanisms would be more desirable 
than applicator devices, especially if the cost could be kept low. Such systems have recently been described 
[39,56,57]. 
Dissolving MN systems loaded with hydrophobic NPs are likely to be manufactured in two stages to avoid waste 
of drug (Figure 3a). The baseplate could be separately produced as a polymeric film using well-established knife-
casting techniques. Mixing a freeze-dried NP powder with a polymeric gel or adding polymer powder directly to a 
concentrated nanosuspension might be required to maximize drug loading in the needles of the array. A suitable 
mold could be filled by the particle-loaded gel by a range of methods, including applying a vacuum or utilising 
compressed air. Needles and baseplate can then be merged before or after drying, using a thin adhesive layer, if 
necessary. For most drugs, the NPs are likely to have to be distributed throughout the entire length of the needles 
(Figure 3b), which could be increased to further enhance the drug-loading capacity, while taking care not to exceed 
1 mm, in which case pain and pinprick bleeding can occur. However, for potent hormones, the MN could be formed 
by two gel castings so as to localize the drug in the needle tips alone (Figure 3c). 
Some of the manufacturing approaches previously described have been evaluated by different research groups 
for the laboratory-scale preparation of MNs. However, one of the important challenges in MN technology is the 
scale-up the manufacturing processes. Several studies described new processes to improve the manufacturing of 
MN arrays [58,59]. Lutton et al. described a scalable method for MN production using a micromolding procedure 
[58]. The described method can be easily applied to the manufacturing of nanosuspension-containing MN arrays. 
Nevertheless, there is another key issue that needs to be addressed to design a suitable manufacturing process: 
product sterility/low bioburden requirements [60]. As described previously, the regulatory bodies have not yet 
defined the requirements for MN products in terms of sterility. Consequently, the manufacturing procedures 
should be designed with this challenge in mind. 
Concluding remarks 
Dissolving MN delivery systems have been shown to deliver NPs into the viable skin layers in vitro and in vivo [55] 
and have the capability to incorporate and release high doses of undissolved solids [26]. Accordingly, their potential 
as a next-generation delivery system for emerging long-acting nanosuspensions is becoming clear. Indeed, the first 
report of the development and successful in vivo evaluation of such a combination system was recently presented 
[61]. To date, MNs, including dissolving MNs, have been rather narrowly viewed as vaccine delivery systems for the 
developing world. However, the demonstrated ability of properly formulated systems to incorporate and release 
high drug doses should soon begin to change this mindset. One could view the dissolving MN simply as a tool to 
deposit the ‘real’ delivery system, the drug nanosuspension, in the viable skin layers in sufficient amounts to allow 
prolonged drug administration. It is likely that we will soon see an increasing number of hydrophobic solid drug 
nanoparticulate systems delivered using dissolving MNs, with a variety of therapeutic indications. For translation 
to clinic and, ultimately market, methods of manufacture will need to be refined and scaled up [62] and the 
‘microneedle’ aspect of the name of the final patch systems removed. The term currently being used by the World 
Health Organization for all microneedle-based systems is ‘microarray patches’, or MAPs. Such an adjustment 
might appear minor, but could be important for patient acceptance. Dissolving MAPs could well be the dosage form 
of the near future, with needle-free administration of long-acting drug nanosuspensions an exciting application 
with a range of potential benefits for patients and healthcare providers, especially in the poorest countries of the 
world. Watch this space! 
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Figure 1. Microneedle (MN) designs. Wet-etched silicon MNs approximately 280 Mm in height suitable for coating with capture proteins or antibodies (a,b). MNs 
approximately 600 Mm in height produced from micromolding of aqueous gels of poly(methylvinylether-co-maleic acid) and poly(ethylene glycol) (PEG) 10 000 that 
swell in skin to capture skin interstitial fluid (c). Poly(carbonate) MNs approximately 1000 Mm in height with a 100 Mm off-center through-hole suitable for blood 
extraction (d), Orion Helium-ion microscope images of 7-MN arrays of this design (e) and 3D optical coherence tomographic representation of these MNs in situ, 
following insertion into excised neonatal porcine skin in vitro (f). Swollen hydrogel-forming MNs approximately 600 Mm in height produced from micromolding of 
aqueous gels of poly(methylvinylether-co-maleic acid) and PEG 10 000 completely intact following removal from skin (g) and MNs approximately 280 Mm in height 
produced from micromolding of aqueous gels of poly(methylvinylether-co-maleic acid) and glycerol following removal from skin (h). The latter type of hydrogel-forming 
MNs following uptake of meso-tetra (N-methyl-4-pyridyl) porphine tetra tosylate in vitro (I). Hydrogel-forming MNs approximately 600 Mm in height produced from 
micromolding of aqueous gels of poly(methylvinylether-co-maleic acid) and PEG 10 000 swelling in human skin in vivo (j). 
Figure 2. Microneedle (MN) delivery strategies. A schematic representation of five different MN types used to facilitate drug delivery transdermally. (a) Solid MNs for 
increasing the permeability of a drug formulation by creating microholes across the skin. (b) Coated MNs for rapid dissolution of the coated drug into the skin. (c) 
Dissolvable MNs for rapid or controlled release of the drug incorporated within the MNs. (d) Hollow MNs used to puncture the skin and enable release of a liquid drug 
following active infusion or diffusion of the formulation through the needle bores. (e) Hydrogel-forming MNs take up interstitial fluids from the tissue, inducing diffusion of 
the drug located in a patch through the swollen microprojections. 
Figure 3. Microarray patches loaded with long-acting nanosuspensions. Preparation of microarray patches using aqueous polymeric gels containing solid-drug 
nanosuspensions where the preformed baseplate is added after initial casting of the gel into the molds (a). Delivery of solid-drug nanosuspensions into skin where the 
particles are loaded into the entire shaft length of the microneedles (MN) (b). Delivery of solid-drug nanosuspensions into skin where the particles are loaded into the 
MN tips only (c). 
 
 
 
 
  
 
 
 
  
 
  
 Table 1. Completed and ongoing clinical trials using MNsa  
Conditions Status Phase Year 
Vaccination/skin absorption Ongoing – 2017 
Primary axillary hyperhidrosis Completed – 2017 
Hyperhidrosis Completed Phase 1 2017 
Migraine Ongoing Phase 3 2017 
Periodontoclasia/gingiva; injury/condition/blood clot/gingiva disorder Ongoing – 2017 
Macular edema/retinal vein occlusion Ongoing Phase 3 2017 
Diabetic macular edema Ongoing Phase 2 2017 
Uveitis/uveitis, posterior/uveitis, anterior/uveitis, intermediate/panuveitis Ongoing Phase 3 2017 
Psoriasis/administration, topical Ongoing – 2016 
Dental pain/anesthesia, local Ongoing – 2016 
Diabetes mellitus Ongoing – 2016 
Allergic reaction to nickel Completed – 2016 
Primary axillary hyperhidrosis Ongoing – 2016 
Acute migraine Completed Phase 2/3 2016 
Type 1 diabetes mellitus Ongoing Phase 1 2016 
Vitiligo – macular depigmentation Ongoing – 2016 
Central retinal vein occlusion Ongoing Phase 1 2016 
Vitiligo Ongoing – 2016 
Diabetic macular edema Completed Phase 1/2 2016 
Uveitis/uveitis, posterior/uveitis, anterior/uveitis, Intermediate/panuveitis Ongoing – 2016 
Pain Completed – 2015 
Aging Unknown status – 2015 
Influenza Ongoing Phase 1 2015 
Keratosis, actinic Completed – 2015 
Actinic keratosis Completed Phase 2 2015 
Hypoglycemia Completed Phase 1 2015 
Crow’s feet wrinkles Completed Phase 4 2015 
Healthy (comparison of mechanical penetration enhancers on Metvixia skin penetration) Completed Phase 1 2015 
Renal failure Ongoing Phase 2/3 2015 
Postmenopausal osteoporosis Completed Phase 1 2015 
Healthy (pretreatments of the skin prior to photodynamic therapy) Completed Phase 1 2015 
Uveitis/uveitis, posterior/uveitis, anterior/uveitis, intermediate/panuveitis Ongoing Phase 3 2015 
Cutaneous T cell lymphoma Ongoing Phase 1 2014 
Varicella zoster infection Ongoing – 2014 
Complications associated with artificial fertilization/placenta; implantation/pregnancy Terminated – 2014 
Androgenetic alopecia Unknown status Phase 1 2014 
Acne/scar Completed – 2014 
Uveitis/macular edema/uveitis, posterior/uveitis, anterior/panuveitis/uveitis, intermediate Completed Phase 2 2014 
Actinic keratosis Completed – 2013 
Intracutaneous drug delivery Completed – 2013 
Uveitis/intermediate uveitis/posterior uveitis/panuveitis/non-infectious uveitis Completed Phase 1/2 2013 
Influenza Completed – 2013 
Acne/scar Unknown status – 2013 
Overactive bladder Completed – 2013 
Poliomyelitis Completed Phase 3 2013 
Optimization of TB intradermal skin test Completed – 2012 
Birch pollen allergy Completed Phase 1 2012 
Type 1 diabetes mellitus Ongoing Phase 2 2012 
Diabetes mellitus Completed Phase 1/2 2012 
Chronic Illness Completed – 2012 
Postmenopausal osteoporosis Completed Phase 2 2012 
Atopic dermatitis Completed Early Phase 1 2012 
Dermatitis, atopic Completed – 2012 
Polio immunity Completed Phase 2 2012 
Influenza Completed Phase 1/2 2012 
Influenza Completed – 2011 
Influenza vaccine Completed Phase 4 2011 
Pain perception/phlebotomy Withdrawn Phase 2/3 2010 
Influenza infection Completed – 2010 
Type 1/2 diabetes mellitus Completed Phase 1/2 2010 
Healthy (tolerability study of application of MN arrays) Completed Phase 1 2010 
Type 1 diabetes mellitus Completed Phase 2/3 2009 
Healthy (assessment of safety and immunogenicity of influenza vaccine administered via 
MN arrays) 
Unknown status – 2009 
Intradermal Injections Completed Early Phase 1 2008 
Local anesthesia/intradermal Injections Completed – 2007 
Influenza, human Completed – 2007 
aData from https://clinicaltrials.gov/. 
 
 
